Tigecycline in treatment of multidrug-resistant Gram-negative bacillus urinary tract infections: A systematic review

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 10, 2014, Pages 2606-2610

  Brust, K ^a   Evans, A ^b   Plemmons, R ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

Acinetobacter baumannii; Carbapenem resistant Enterobacteriaceae; GAR 936; Klebsiella pneumoniae; KPC

Indexed keywords

TIGECYCLINE; ANTIINFECTIVE AGENT; MINOCYCLINE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; DRUG EFFICACY; GRAM NEGATIVE BACTERIUM; HUMAN; OUTCOME ASSESSMENT; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; CLASSIFICATION; CROSS INFECTION; DRUG EFFECTS; FEMALE; MALE; META ANALYSIS; MICROBIOLOGY; MULTIDRUG RESISTANCE; RISK FACTOR; URINARY TRACT INFECTIONS;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIA; HUMANS; MALE; MINOCYCLINE; RISK FACTORS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 84909988269     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku189     Document Type: Review

References (27)

1. Muralidharan G, Micalizzi M, Speth J et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49: 220-9.
2. Rodvold KA, Gotfried MH, Cwik M et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006; 58: 1221-29.
3. Brust K, Evans A, Plemmons R. Favourable outcome in the treatment of carbapenem-resistant Enterobacteriaceae urinary tract infection with high-dose tigecycline. J Antimicrob Chemother 2014; 69: 2875-6.
4. Anthony KB, Fishman NO, Linkin DR et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin Infect Dis 2008; 46: 567-70.
5. Cunha BA. Single daily high-dose tigecycline therapy of a multidrugresistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection. J Chemother 2007; 19: 753-4.
6. Elemam A, Rahimian J, MandellW. Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin Infect Dis 2009; 49: 271-4.
7. Gallagher JC, Rouse HM. Tigecycline for the treatment of Acinetobacter infections: a case series. Ann Pharmacother 2008; 42: 1188-94.
8. Geerlings SE. Successful treatment with tigecycline of two patients with complicated urinary tract infections caused by extended-spectrum b-lactamase-producing Escherichia coli. J Antimicrob Chemother 2010; 65: 1145-54.
9. Krueger WA, Kempf VA, Peiffer M et al. Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-b-lactamaseproducing Escherichia coli. J Clin Microbiol 2008; 46: 817-20.
10. Kuo SC, Wang FD, Fung CP et al. Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients. J Microbiol Immunol Infect 2011; 44: 45-51.
11. Reid GE. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007; 27: 1198-201.
12. Drekonja DM, Johnson JR. Tigecycline treatment for urinary tract infections: case report and literature review. J Chemother 2011; 23: 168-70.
13. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 Suppl 1: S1-266.
14. Tygacilw (Tigecycline For Injection) Package Insert. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021821s021lbl.pdf (20 May 2014, date last accessed).
15. Meagher AK, Ambrose PG, Grasela TH et al. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005; 41 Suppl 5: S333-40.
16. Hoffmann M, DeMaio W, Jordan RA et al. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab Dispos 2007; 35: 1543-53.
17. Nicasio AM, Crandon JL, Nicolau DP. In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 2009; 53: 2756-61.
18. Korth-Bradley JM, Troy SM,Matschke K et al. Tigecycline pharmacokinetics in subjects with various degrees of renal function. J Clin Pharmacol 2012; 52: 1379-87.
19. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005; 41 Suppl 5: S303-314.
20. Sesoko S, Umemura K, Nakashima M. Pharmacokinetics (PK), safety, and tolerability of tigecycline (GAR-936) in healthy Japanese males. In: Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract A-1403, p. 22. American Society for Microbiology, Washington, DC, USA.
21. Nix DE, Matthias KR. Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation. J Antimicrob Chemother 2010; 65: 1311-2.
22. Gardiner D, Dukart G, Cooper A et al. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis 2010; 50: 229-38.
23. Quereshi ZA, Paterson DL, Kilayko MC et al. Treatment outcomes of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012; 56: 2108-13.
24. Cunha BA. Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis. J Clin Microbiol 2009; 47: 1613.
25. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54: 1699-709.
26. FDA Drug Safety Communication: FDAWarns of Increased Risk of Death with IVAntibacterial Tygacil (Tigecycline) and Approves new BoxedWarning. http://www.fda.gov/Drugs/DrugSafety/ucm369580.htm# (2 January 2014, date last accessed).
27. Nicolau DP. Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline. Expert Opin Pharmacother 2009; 10: 1213-22.